AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02239861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-Specific CTLs
Description: Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
Study NCT03481556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan flufenamide (Melflufen)
Description: Intravenous infusion
Study NCT03481556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets
Study NCT03481556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous administration
Study NCT03481556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous infusion
Study NCT02741713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS Pectoralis 1 and 2 Blocks
Description: An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects.
Study NCT02741713 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Interscalene Block
Description: An interscalene block will be performed on the subjects.
Study NCT02741713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: An interscalene block will be performed on the subjects.
Study NCT02741713 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Block
Study NCT02741713 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Solution for Injection in Interscalene Block
Description: 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
Study NCT02741713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Injection in Interscalene Block
Description: 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
Study NCT02741713 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Solution for Injection in Sham Block
Description: Lidocaine 1%
Study NCT02741713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution for Injection PECS Blocks
Description: 10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
Study NCT01272323 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placebo
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Study NCT01272323 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cat-PAD Dose 1
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Study NCT01272323 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cat-PAD Dose 2
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
Study NCT01516853 — intervention group
Intervention type: DEVICE
Intervention: Non-contrast MRI
Description: Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
Study NCT02142998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24 pH monitoring
Description: The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
Study NCT02142998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Manometry:
Description: A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg PO Daily for 28 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg PO Daily for 28 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg PO Daily for 28 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO Daily for 21 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 25 mg PO Daily for 21 Days Every 28 Days
Study NCT00495872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Group 1: Will receive donepezil 5mg once a day
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: Group 2: Will receive duloxetine 30 mg twice a day
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil 2.5 mg and duloxetine 30mg
Description: Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 4: Will receive placebo pills
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication
Study NCT00619983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication
Study NCT04546659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrowalking
Description: Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
Study NCT04546659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
Study NCT04546659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
Study NCT01984671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Pain Coping Skills Training
Study NCT00809341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study NCT00630591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Assisted Tailored Intervention
Description: Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
Study NCT03362801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: sarcopenia and mobility measurement
Description: walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment
Study NCT01678703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria, MedGyn Products, Inc. USA.
Description: Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
Study NCT01678703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
Study NCT03822494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT
Description: Radiation Therapy
Study NCT01715519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment (Viibryd)
Study NCT01715519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment (Viibryd)
Study NCT03745105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
Study NCT03745105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam Injectable Solution
Description: prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
Study NCT03745105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine HCL
Description: prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
Study NCT01935713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
Study NCT01935713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
Study NCT01935713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dissolvable Tobacco Lozenge
Description: Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, >2 packs per day).
Study NCT02103257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Icotinib Plus Chemotherapy
Description: Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
Study NCT02103257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
Study NCT05528484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS nursing
Description: Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
Study NCT05528484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non eras nursing
Description: Patients were under the routine management without eras protocol
Study NCT01448863 — intervention group
Intervention type: OTHER
Intervention: Culture medium metabolomic analysis
Description: During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile.
Study NCT00819572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
Description: Comparison of two different doses of intra-articular DLX105
Study NCT00819572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04667533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desidustat
Description: A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg
Study NCT01530724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-loss diet strategy (+) exercise (PA)
Description: Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
Study NCT01530724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss (-) exercise (PA)
Description: Weight-loss diet strategy without exercise
Study NCT01375634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
Study NCT01375634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
Study NCT00763516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation and chemotherapy
Description: Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses
Study NCT00928655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: acetazolamide 250mg 1/0/2
Study NCT00928655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nocturnal continuous positive airway pressure
Description: continuous positive airway pressure
Study NCT00928655 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nocturnal continuous positive airway pressure
Description: continuous positive airway pressure
Study NCT00928655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiotepa
Description: Given IV
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00809341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Given IV or orally
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or orally
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given IV
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00382109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally
Study NCT00382109 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Part of the transplant preparatory regimen
Study NCT00382109 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: Part of the transplant preparatory regimen
Study NCT01159639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
Study NCT03655873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC30654AcOH capsule
Description: single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday.
Study NCT03655873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday.
Study NCT02668237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiPAC
Description: Molecular and urinary tests.
Study NCT02668237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Antibiotics for prevention.
Study NCT01941004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Description: Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Study NCT01941004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (6mos) + open label fingolimod (6 mos)
Description: Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Study NCT02415998 — intervention group
Intervention type: PROCEDURE
Intervention: TEE
Description: Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
Study NCT02773264 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound Elastography of soft tissue and organ lesions
Study NCT01736358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketoralac
Description: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery
Study NCT01736358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
Study NCT01695122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study NCT01132196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study NCT01132196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study NCT01097460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-111 + Herceptin
Description: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
Study NCT04039503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.
Study NCT04039503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC as add-on to the pre-trial background medication.
Study NCT02413684 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient engagement toolkit
Description: Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care
Study NCT04436796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interoperable Artificial Pancreas System (iAPS)
Description: Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.